Bris­tol-My­ers of­fers a pos­i­tive snap­shot on ear­ly da­ta for an IDO1 ri­val to In­cyte

WASH­ING­TON, DC — While In­cyte and the founders of Flexus scrap in court over who owns the IDO1 tech­nol­o­gy that Bris­tol-My­ers Squibb $BMY bought in a $1.25 bil­lion deal a cou­ple of years ago, Bris­tol-My­ers is ready to start putting the ear­ly-stage da­ta from a com­bi­na­tion study with Op­di­vo on dis­play.

To­day at the SITC meet­ing, in­ves­ti­ga­tors say their on­go­ing Phase I/II study of the check­point drug Op­di­vo plus BMS-986205 pro­duced some vary­ing pos­i­tive re­sults for heav­i­ly pre-treat­ed blad­der (25 cas­es) and cer­vi­cal can­cer pa­tients (22 pa­tients).

Bot­tom line:

— In the blad­der can­cer co­hort, the ob­jec­tive re­sponse rate and dis­ease con­trol rate were 32% and 44%, re­spec­tive­ly.

— In the cer­vi­cal can­cer co­hort, the ORR was 14% and DCR was 64%.

PD-L1 ex­pres­sion mat­tered. Ze­ro­ing in on pa­tients who ex­press PD-L1 more than 1%, ORR was 46% and 25% in the blad­der and cer­vi­cal can­cer groups, re­spec­tive­ly, while for pa­tients who ex­press PD-L1 less than 1%, ORR was 22% in the blad­der can­cer co­hort with no re­spons­es ob­served in cer­vi­cal can­cer pa­tients.

In a court case filed in Delaware, In­cyte claimed that Jor­dan Frid­man, a sci­en­tist in its ranks, had sys­tem­at­i­cal­ly lift­ed its IDO1 se­crets be­fore mak­ing his way to Flexus, which sub­se­quent­ly ac­cept­ed a jaw-drop­ping buy­out of­fer from Bris­tol-My­ers. The law­suit filed against Flexus founders Ter­ry Rosen and Juan Jean seeks more than a bil­lion dol­lars in dam­ages.

In­cyte $IN­CY has the most ad­vanced IDO1 in the clin­ic — epaca­do­stat — and is clear­ly in­tent on de­fend­ing its IP turf. Bris­tol-My­ers, mean­while, is plac­ing a heavy em­pha­sis on mov­ing as fast as pos­si­ble on the IDO1 front as it push­es ahead with its big check­point ther­a­py and com­bos around it.

Bris­tol-My­ers IDO de­vel­op­ment lead Mark Rut­stein not­ed:

We are ur­gent­ly pur­su­ing trans­for­ma­tive re­search to bet­ter un­der­stand tu­mor eva­sion mech­a­nisms to help in­form po­ten­tial new treat­ment op­tions for pa­tients with ad­vanced can­cers. BMS-986205 has shown en­cour­ag­ing char­ac­ter­is­tics, in­clud­ing po­tent and se­lec­tive in­hi­bi­tion of IDO1, as well as phar­ma­co­ki­net­ic da­ta that sup­port once-dai­ly dos­ing. We look for­ward to ad­di­tion­al da­ta from this study.

Grow­ing ac­cep­tance of ac­cel­er­at­ed path­ways for nov­el treat­ments: but does reg­u­la­to­ry ap­proval lead to com­mer­cial suc­cess?

By Mwango Kashoki, MD, MPH, Vice President-Technical, and Richard Macaulay, Senior Director, of Parexel Regulatory & Access

In recent years, we’ve seen a significant uptake in the use of regulatory options by companies looking to accelerate the journey of life-saving drugs to market. In 2018, 73% of the novel drugs approved by the U.S. Federal Drug Administration (FDA) were designated under one or more expedited development program categories (Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval).ᶦ

Sanofi out­lines big API plans as coro­n­avirus out­break re­port­ed­ly threat­ens short­age of 150 drugs

As the world becomes increasingly dependant on Asia for the ingredients of its medicines, Sanofi sees business to be done in Europe.

The French drugmaker said it’s creating the world’s second largest active pharmaceutical ingredients (API) manufacturer by spinning out its six current sites into a standalone company: Brindisi (Italy), Frankfurt Chemistry (Germany), Haverhill (UK), St Aubin les Elbeuf (France), Újpest (Hungary) and Vertolaye (France). They have mapped out €1 billion in expected sales by 2022 and 3,100 employees for the new operations headquartered in France.

Bio­gen touts new ev­i­dence from the gene ther­a­py com­pa­ny it wa­gered $800M on

A year ago, Biogen made a big bet on a small gene therapy company. Now they have new evidence one of their therapies could work.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 73,000+ biopharma pros reading Endpoints daily — and it's free.

Anthony Fauci (AP Images)

UP­DAT­ED: NIH-part­nered Mod­er­na ships off its PhI-ready coro­n­avirus vac­cine can­di­date to a sea of un­cer­tain­ty

Off it goes.

Moderna has shipped the first batch of its mRNA vaccine against SARS-CoV-2 from its manufacturing facility in Norwood, Massachusetts, to the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, for a pioneering Phase I study.

It’s a hectic race against time. In the 42 days since Moderna selected the sequence they would use to develop their vaccine — a record time, no less — the number of confirmed cases around the world has surged astronomically from a few dozen to over 80,000, per WHO and Johns Hopkins estimates.

The candidate that they came up with, mRNA-1273, encodes for a prefusion stabilized form of the spike protein, which gives the virus its crown shape and plays a key role in transmission. The Coalition for Epidemic Preparedness Innovations, the Oslo-based group better known as CEPI, funded the manufacture of this batch.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 73,000+ biopharma pros reading Endpoints daily — and it's free.

In fi­nal re­port, ICER ap­pears to have a change of heart on new acute mi­graine ther­a­pies

ICER appears to have reversed course on the fresh crop of acute migraine therapies.

The cost-effectiveness watchdog in November issued a draft report suggesting that existing generic medicines are more effective and cheaper than Allergan’s December-approved CGRP ubrogepant, Biohaven rival molecule, rimegepant (which is under FDA review), and Lilly’s October-sanctioned lasmiditan, which binds to 5-HT1F receptors.

Bi­cy­cle Ther­a­peu­tics takes Roche's Genen­tech on an up to $2B im­muno-on­col­o­gy ride

Bicycle Therapeutics — which is developing a new class of chemically synthesized drugs designed to be pharmacologically as active as biologics, yet manufactured as small molecules —  has scored another big partner: Roche’s Genentech.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 73,000+ biopharma pros reading Endpoints daily — and it's free.

When drug val­ue as­sess­ment meets re­al-world ev­i­dence: ICER en­lists Ae­tion in pric­ing eval­u­a­tion

In a union of two of the hottest trends in the US biopharma world, ICER is teaming up with a high-profile company to integrate real-world evidence in their assessment of treatment value.

The drug pricing watchdog — formally the Institute for Clinical and Economic Review — said it will utilize Aetion’s evidence platform in “select upcoming assessments” and their new 24-month re-evaluations of drugs granted accelerated approval by the FDA.

Anthony Fauci, AP Images

First US Covid-19 tri­als set to get un­der­way in Ne­bras­ka and Wash­ing­ton, backed by NIH

The first US clinical trials on the novel coronavirus are scheduled to get underway next month at the University of Nebraska Medical Center, where American passengers were taken after being evacuated from the Diamond Princess cruise ship, and at the Kaiser Permanente Washington Health Research Institute. Both trials are sponsored by the NIH’s National Institute for Allergy and Infectious Diseases, which has led the US’s medical response to the outbreak.

UP­DAT­ED: NGM Bio takes leap for­ward in crowd­ed NASH field

South San Francisco-based NGM Bio may have underwhelmed with its interim analysis of a key cohort from a mid-stage NASH study last fall — but stellar topline data unveiled on Monday showed the compound induced significant signs of antifibrotic activity, NASH resolution and liver fat reduction, sending the company’s stock soaring.

There are an estimated 50+ companies focused on developing drugs for non-alcoholic steatohepatitis, or NASH, a common liver disease that has long flummoxed researchers. The first wave of NASH drug developers struggled with efficacy as well as safety — and companies big and small have crashed and burned.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 73,000+ biopharma pros reading Endpoints daily — and it's free.